Post by HEALTHCARE INSIGHTS

𝗠𝗲𝗿𝗰𝗸 𝗞𝗚𝗮𝗔 𝗔𝗰𝗾𝘂𝗶𝗿𝗲𝘀 𝗕𝗶𝗼-𝗧𝗲𝗰𝗵𝗻𝗲 𝗜𝗻 𝗔𝗻 $𝟭𝟭.𝟯 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗗𝗲𝗮𝗹 𝗧𝗼 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻 𝗜𝘁𝘀 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗜𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 Merck KGaA has agreed to acquire Bio-Techne in an all-cash transaction valued at approximately $11.3 billion, marking its largest Life Science acquisition since the landmark Sigma-Aldrich deal in 2015. Unlike many pharmaceutical acquisitions focused on drug pipelines, Bio-Techne supplies the essential research tools that power modern biotechnology including antibodies, cytokines, growth factors, protein analysis platforms, and diagnostic reagents used throughout drug discovery and manufacturing. The acquisition significantly strengthens Merck KGaA's position as an infrastructure provider to the global life sciences industry, particularly across cell & gene therapy, precision medicine, and advanced biomanufacturing. As biopharmaceutical R&D becomes increasingly complex, owning the technologies that enable research may prove just as valuable as owning the medicines themselves. The deal reflects a broader industry shift toward investing in scientific infrastructure that supports innovation across thousands of therapeutic programs. 🔗 Is the next competitive advantage in biotech no longer about owning the best drugs but about owning the platforms that make those drugs possible? 👉 Read the full article via the link below to explore Merck KGaA's strategy, Bio-Techne's role, and how this acquisition could reshape the future of the global life sciences industry. Link: https://lnkd.in/ghsaPhUG Curated by HEALTHCARE ALLIANCE VIETNAM #ALZpath #Abbott #AlzheimersDisease #Diagnostics #IVD #Biomarkers #PrecisionMedicine #MedTech #HealthcareInnovation #PharmaBiz